Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.
Palliative care is a recommended part of heart failure management in the U.S., but consultation rates remain low. The trend appears to impact Black patients more than other races and ethnicities.
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.
Early detection of cardiac amyloidosis is leads to the best outcomes, but it is often missed until later stages. AI is being developed to help detect these patients earlier using ECG and echo.
Researchers explored data from 23 different studies, identifying a “positive and almost linear association” between alcohol consumption and hypertension.
Paul Zei, MD, discusses late-breaking data from the REAL-AF Registry, which looked at the short- and long-term outcomes of radiofrequency ablation in paroxysmal and persistent atrial fibrillation.
Researchers developed an advanced AI model capable of extracting measurements from unprocessed CT images in seconds. It then uses those data to evaluate the patient's mortality risk if they underwent TAVR.
Devi Nair, MD, director of cardiac electrophysiology with St. Bernard's Heart and Vascular Center, discussed her experience using a new-look Medtronic pulsed field ablation (PFA) system to treat persistent AFib.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.